NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

NCT05664217 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decided to end the study

Conditions

Non-Hodgkin Lymphoma
Relapsed/Refractory Diffuse Large B-cell Lymphoma

Interventions

DRUG: NKTR-255 at 1.5 µg/kg
DRUG: NKTR-255 at 3.0 μg/kg
DRUG: NKTR-255 at 3.0/6.0 μg/kg
OTHER: Placebo Comparator

Sponsor

Nektar Therapeutics